Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Q1 FY2023 Earnings Presentation
15 slides from Par Drugs And Chemicals's earnings presentation, Aug 9, 2022
Slide 1: Cover letter to NSE: Investors Presentation
PAR/CS/NSE/2022-23/30 To, Date: 09/08/2022 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR, ISIN: INE04LG01015 Subject: Investors Presentation Ref.: Regulation 30 read wi
Slide 2: Q1-FY23 Earnings Presentation
Q1-FY23 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
3 Company Overview Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 209 and manufacturing of APIs. 194 218 • The Company today manufactures 25 different products and all
Slide 5: Key Strengths
4 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and ex
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: Q1-FY23 Financial & Operational Highlights
6 Q1-FY23 Financial & Operational Highlights Operational Highlights • For Q1-FY23, sales grew by around 43% YOY, driven by a sales growth in the domestic market of 35% and in the Q1-FY23 Financial Highlights export market of 74% YOY. • In our sales product mix, there has been an increase in the sale
Slide 8: Q1-FY23 Financial Overview
Q1-FY23 Financial Overview
Slide 9: Quarterly Financial Performance (IND-AS)
8 Quarterly Financial Performance (IND-AS) Income Statement (INR Mn) Q1-FY23 Q1-FY22 Y-o-Y Q4-FY22 Q-o-Q Income from Operations 235 165 42.4% 221 6.3% Total Expenses 198 124 59.7% 176 12.5% EBITDA 37 41 (9.8)% 45 (17.8)% EBITDA Margins (%) 15.74% 24.85% (911)Bps 20.36% (462)Bps Finance Cost 1 - NA 1
Slide 10: Historical Income statement
9 Historical Income statement Income Statement (INR Mn) FY20 FY21 FY22 Q1-FY23 Income from Operations 558 608 751 235 Total Expenses 464 447 588 198 EBITDA 94 161 163 37 EBITDA Margins (%) 16.85% 26.48% 21.70% 15.74% Finance Cost 8 7 5 1 Depreciation 27 28 33 7 Other Income 1 2 2 2 Profit before Ext
Slide 11: Balance Sheet
10 Balance Sheet EQUITIES & LIABILITIES (INR Mn) FY20 FY21 FY22 ASSETS (INR Mn) FY20 FY21 FY22 Shareholder Funds 406 522 599 Non Current Assets 359 352 351 (A) Equity Share Capital 61 61 123 (A) Fixed Assets - - (B) Reserves & Surplus 345 461 476 (i) Tangible Assets 344 299 341 (ii) Capital work-in-
Slide 12: Financial Highlights
11 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 751 26.48% 608 21.70% 19.08% 558 16.85% 12.25% 15.74% 8.60% 9.79% 235 116 92 94 161 163 37 48 23 FY20 FY21 FY22 Q1-FY23 FY20 FY21 FY22 Q1-FY23 FY20 FY21 FY22 Q1-FY23 RoCE & RoE Ne
Slide 13: Capital Market Highlights
12 Capital Market Highlights Stock Market Performance (as on 30th June, 2022) 240% 190% 140% 90% 40% -10% Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Par Drugs Nifty 50 52 Price Data (30th June, 2022) INR Shareholding Pattern as on 30th June, 2022 Face Value 1
Slide 14: Disclaimer
13 Disclaimer Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection w
Slide 15: Thank You
Thank You
Par Drugs and Chemicals — Q1 FY2023 Earnings Presentation on 6ix